Robert Marciano, DO
Family Medicine · Mobridge, SDNPI 1427030949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $999 and has fallen 85.5% since, to $144 in 2025. Among family medicine clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$475
- Novo Nordisk$462
- Astellas Pharma US Inc$372
- Johnson & Johnson$339
- AbbVie$330
- Lilly USA, LLC$301
- plus $2K from 14 others
What the payments were for
- Food & beverage$3,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 28 | $475 |
| Novo Nordisk | 32 | $462 |
| Astellas Pharma US Inc | 20 | $372 |
| Johnson & Johnson | 27 | $339 |
| AbbVie(2 entities) | 17 | $330 |
| Lilly USA, LLC | 20 | $301 |
| AstraZeneca | 16 | $252 |
| Merck | 24 | $236 |
| Novartis | 13 | $229 |
| Sanofi-aventis U.S. LLC | 11 | $182 |
| Boehringer Ingelheim | 11 | $170 |
| Pfizer | 10 | $133 |
| Exact Sciences | 6 | $97 |
| E.r. Squibb & Sons, L.L.C. | 6 | $90 |
| Bayer | 3 | $41 |
| Smith+Nephew | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Edwards Lifesciences | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
How this compares
$3,812 in reported general payments places this provider in the 95th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 108 | $63,729 |
| JardianceEmpagliflozin | 76 | $45,986 |
| OzempicSemaglutide | 43 | $41,137 |
| JanuviaSitagliptin Phosphate | 34 | $19,434 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $16,265 |
| FarxigaDapagliflozin Propanediol | 19 | $14,727 |
| MyrbetriqMirabegron | 23 | $13,334 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $12,522 |
| MounjaroTirzepatide | 11 | $11,323 |
| InvokanaCanagliflozin | 20 | $11,082 |
| Bydureon BciseExenatide Microspheres | 12 | $10,261 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $5,946 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 11 | $3,353 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,429 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $133 | $63,729108 claims |
| Boehringer IngelheimJardiance | $170 | $45,98676 claims |
| Novo NordiskOzempic | $462 | $41,13743 claims |
| MerckJanuvia, Janumet Xr | $236 | $25,37949 claims |
| AstraZenecaFarxiga | $252 | $14,72719 claims |
| Astellas Pharma US IncMyrbetriq | $372 | $13,33423 claims |
| Lilly USA, LLCMounjaro | $301 | $11,32311 claims |
| Johnson & JohnsonInvokana | $339 | $11,08220 claims |
| AbbVieSynthroid | $330 | $1,02711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Mobridge
- Matthew SchafferMobridge$4K
- Emily BodenMobridge$3K
- Kyla Helm-SwansonRapid City$22K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
- Scott BoyensSioux Falls$6K
- Terry GraberCuster$6K
- Christi ChildersSpearfish$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.